Market research
BJ93.F Benitec Biopharma Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 302K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 302K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
About
About Benitec Biopharma Inc
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Research context
Benitec Biopharma Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BJ93.F discussion.
5 years, 7 months ago
Benitec Biopharma Inc is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 81.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 238.1.
Benitec Biopharma Inc's total revenue sank by 98.7% to $1K since the same quarter in the previous year.
Its net income has dropped by 51.3% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 11.3% to $-4M since the same quarter in the previous year.
Based on the above factors, Benitec Biopharma Inc gets an overall score of 1/5.